Supplemental File: Non-cutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy
Published: 16 December 2022| Version 1 | DOI: 10.17632/mrdyhdh78k.1
Edward Christopher Dee,
This file includes additional details on study methodology and supplemental figures (Kaplan-Meier curves).
Dermatology, Cancer Immunotherapy, Drug Adverse Reactions, Survival Analysis, Medical Oncology